Serum lipid peroxides in patients with Parkinson's disease.
To elucidate whether high serum lipid peroxidation rates may increase the risk of developing Parkinson's disease (PD), we assessed serum levels of malondialdehyde (MDA), an intermediate in lipid peroxidation processes, in 37 PD patients, with their spouses as the control group. Serum MDA levels did not differ significantly between these two groups (8.7 +/- 0.51 and 8.8 +/- 0.48 nmol/ml, resp.), and were not influenced by antiparkinsonian therapy in the PD patients. Serum MDA levels were inversely correlated with age and age at onset (P less than 0.01) in the PD group, but they were not correlated with disease duration, Unified Parkinson's Disease Rating Scale scores or Hoehn and Yahr staging. In the control group there was no correlation between serum MDA and age. These results suggest that, although serum levels of lipid peroxides were similar in both the PD and control groups, high serum lipid peroxidation rates might constitute a risk factor for younger onset of PD in predisposed individuals.
Molina
J A
JA
Department of Neurology, Hospital Severo Ochoa, Leganés, Madrid, Spain.
Jiménez-Jiménez
F J
FJ
Fernandez-Calle
P
P
Lalinde
L
L
Tenias
J M
JM
Pondal
M
M
Vazquez
A
A
Codoceo
R
R
D000368:Aged; D005260:Female; D006801:Humans; D008054:Lipid Peroxides / Q000097:blood*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D010300:Parkinson Disease / Q000097:blood*; D012307:Risk Factors
D008054:Lipid Peroxides; D008315:Malondialdehyde